Effect of L-Carnitine Supplementation on Secondary Hyperparathyroidism and Bone Metabolism in Hemodialyzed Patients

[1]  A. Nakashima,et al.  Osteoprotegerin and bone mineral density in hemodialysis patients , 2006, Osteoporosis International.

[2]  P. Kostenuik.  Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. , 2005, Current opinion in pharmacology.

[3]  A. Zallone,et al.  L-Carnitine and Isovaleryl L-Carnitine Fumarate Positively Affect Human Osteoblast Proliferation and Differentiation In Vitro , 2005, Calcified Tissue International.

[4]  J. Marc,et al.  Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  J. Cunningham,et al.  New Prospects for the Management of Renal Bone Disease , 2005, Nephron Clinical Practice.

[6]  W. Hörl.  The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  F. Locatelli.  The need for better control of secondary hyperparathyroidism. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  S. Massry,et al.  Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  G. Eknoyan,et al.  Bone metabolism and disease in chronic kidney disease , 2003 .

[10]  T. Shigematsu,et al.  Circulating osteoprotegerin is not removed through haemodialysis membrane. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  J. Marc,et al.  Increased Levels of Osteoprotegerin in Hemodialysis Patients , 2002, Clinical chemistry and laboratory medicine.

[12]  S. Khosla,et al.  Minireview: the OPG/RANKL/RANK system. , 2001, Endocrinology.

[13]  M. Pojer,et al.  Effect of L-Carnitine Supplementation in Hemodialysis Patients , 2001, Nephron.

[14]  A. Nakanishi,et al.  The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  A. Longo,et al.  Pharmacokinetics of L‐carnitine in patients with end‐stage renal disease undergoing long‐term hemodialysis , 2000, Clinical pharmacology and therapeutics.

[16]  P. Ureña,et al.  Circulating biochemical markers of bone remodeling in uremic patients. , 1999, Kidney international.

[17]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[18]  G. Lopaschuk,et al.  Propionyl L-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. , 1995, Circulation research.

[19]  C. Combe,et al.  Phosphorus and protein restriction and parathyroid function in chronic renal failure. , 1994, Kidney international.

[20]  T. Golper,et al.  Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. , 1990, Kidney international.

[21]  R. Morris,et al.  Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. , 1989, The Journal of clinical investigation.

[22]  H. Fleisch,et al.  Fatty acid oxidation in bone tissue and bone cells in culture. Characterization and hormonal influences. , 1987, The Biochemical journal.

[23]  A. Fournier,et al.  Plasma bone Gla-protein: assessment of its clinical value as an index of bone formation in hemodialyzed patients. , 1987, Bone and mineral.

[24]  P. Delmas,et al.  Serum bone Gla-protein in renal osteodystrophy: comparison with bone histomorphometry. , 1986, The Journal of clinical endocrinology and metabolism.

[25]  R. Morris,et al.  Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. , 1984, The Journal of clinical investigation.

[26]  N. Yamazaki,et al.  Effects of L-carnitine on arrhythmias during hemodialysis. , 1981, Japanese heart journal.

[27]  C. Angelini,et al.  CARNITINE DEFICIENCY INDUCED DURING HÆMODIALYSIS , 1978, The Lancet.

[28]  T. Bøhmer,et al.  CARNITINE DEFICIENCY INDUCED DURING INTERMITTENT HÆMODIALYSIS FOR RENAL FAILURE , 1978, The Lancet.

[29]  A. Dusso,et al.  Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  S. Goral.  Levocarnitine's role in the treatment of patients with end-stage renal disease : a review , 2001 .

[31]  G. Paviotti,et al.  Carnitine metabolism in chronic renal failure. , 1987, Kidney international. Supplement.

[32]  E. Trethewie.  Letter: Mental activity and cerebral blood-flow. , 1974, Lancet.

[33]  S. K. Lee,et al.  Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. , 1999, Endocrinology.